Close Menu

financial results

MDx revenues grew 67 percent while centralized and POC solutions revenues were down 13 percent, tissue Dx slid 1 percent and diabetes care declined 10 percent.

Following its recent acquisition of Curetis, OpGen has also shifted its focus onto its Unyvero molecular diagnostics platform and bioinformatics operations.

The company said its clinical lab revenues rose nearly 5 percent, but revenues from its life sciences business fell 26 percent because of the COVID-19 pandemic.

The company's Q3 sales reflect ongoing demand for COVID-19 testing products and improved customer demand in other areas of the firm's portfolio.

The firm said it expects its molecular diagnostics revenues to double year over year with orders continuing to outstrip its supply capabilities. 

Quidel's preliminary earnings more than doubled over the prior quarter on increasing SARS-CoV-2 test sales.

Revenues have begun to recover in Q3, driven by a ramp in SARS-CoV-2 testing, and the firm now expects full-year 2020 revenues to exceed its prior guidance.

The company's revenues for the first half of the year were up over 900 percent on strong sales of its PCR-based SARS-CoV-2 test and related products.

Biocartis noted that it has suspended its partnership with Exact Sciences to develop the Idylla IVD Oncotype Dx Breast Recurrence Score test project due to the pandemic.

For the second quarter, sales for its clinical applications jumped nearly 14 percent, while industrial applications fell 7 percent year over year.

Pages